Protein engineering is an emerging area that has expanded our understanding of protein folding, and laid the groundwork for creation of unprecedented structures with unique functions. We previously designed the first native-like pore-forming protein, small globular protein (SGP). We show here that this artificially engineered protein has membrane-disrupting properties and anti-tumor activity in several cancer animal models. We propose and validate a mechanism for the selectivity of SGP towards cell membranes in tumors. SGP is the prototype for a new class of artificial proteins designed for therapeutic applications.
INTRODUCTION
The tendency of amphipathic peptides to assemble in aqueous solution and of the bturn to form a loop has been successfully employed to design coiled-coil proteins [4] [5] [6] , various helix bundle proteins [7] [8] [9] [10] [11] [12] , and b-structural proteins 13, 14 .
De novo design of proteins with biological function, such as heme-binding, catalysis, or the formation of a membrane pore or channel, is perhaps the most challenging goal of peptide chemistry 3, [15] [16] [17] [18] [19] [20] [21] . Much has been done recently in terms of designing membrane proteins that are correctly incorporated into membranes. However, relatively few attempts have been made to design proteins capable of disrupting membranes and subsequently causing cells death in vivo 21, 22 .
SGP is a 69 amino acid, 4-helix bundle protein, composed of 3 amphipathic helices, which consist of Leu and Lys residues and surround a single hydrophobic helix consisting of Ala residues, which create a pocket-like structure (Fig. 1A, B ) 27, 28 . SGP is monomeric in solution and denatures in a highly cooperative manner, characteristic of native globular-like proteins. SGP was conceived and designed based on the structure of the colicin family of bacteriocins [23] [24] [25] [26] . While most naturally-occurring, pore-forming proteins maintain their tertiary structure when disrupting membranes, the colicins undergo a spontaneous transition from a native folded state in solution to an open umbrella-like state in membranes [23] [24] [25] [26] . Nevertheless, SGP was designed to mimic this membrane insertion mechanism was confirmed in synthetic bilayers, where SGP formed a uniform size pore (14pS) 27 . It is still unknown whether or not SGP oligomerizes to form a channel.
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Quantification of cell death. Cell viability was determined by morphology 29, 30 . For viability assays, KS1767 cells were incubated with the concentrations of SGP, SGP (L), SGP (E), or control peptides indicated in the figures and in Table 1 . Briefly, at the given time points, cell culture medium was aspirated from adherent cells. Cells were then gently washed once with PBS at 37°C. A 20-fold dilution of the dye mixture (100 mg/ml acridine orange and 100 mg/ml ethidium bromide) in PBS was then gently pipetted on the cells and viewed on an inverted microscope (Nikon TE 300). Cells with nuclei exhibiting margination and condensation of chromatin and/or nuclear fragmentation . The mice were anesthetized with Avertin as described 29 . SGP was administered directly into the center of the tumor mass at a concentration of 100mM or 1 mM given slowly in 5 ml increments, for a total volume of 40 ml. Measurements of anesthetized with Avertin. 10 ml of 100 mM SGP or PBS was injected into the skin. The injected areas were monitored for 2 weeks.
Matrigel and cytotoxicity assays. Cell viability was determined by morphology 29, 30 . KS1767 cells were incubated with SGP at 1 mM in the presence or absence of matrigel or polymeric fibronectin (sFN). The fibronectin polymer was produced as described 45 .
Briefly, cell culture medium was aspirated from adherent cells. Cells were then coated with matrigel (gently pipetted on each well in order to completely coat the entire cell layer), or the fibronectin polymer, and incubated at 37°C for 10 minutes. SGP was added and the cells were viewed on an inverted microscope (Nikon TE 300). Cytotoxic assay in vitro and effects of matrigel. KS1767 cells were exposed to doxorubicin (20 mg/well) or SGP in the presence or absense of matrigel for 24 h. Cell viability (%) was evaluated after no treatment (medium or matrigel alone), incubation with SGP or doxorubicin. Cell death was evaluated morphologically 29,30 and cell viability was compared relative to untreated controls (no matrigel), or absence of SGP.
RESULTS

SGP effects on cultured cells.
To evaluate the effects of SGP on cell membranes we treated multiple human cell lines of different origins (Table 1 ). These lines included the Kaposi's sarcoma-derived cell line KS1767, the breast carcinoma-derived cell line MDA-MD-435, and the microvessel endothelial cell line DMEC 32, 33 . Treatment of KS1767 cells with >10 mM SGP led to rapid cell death, characterized by 100% loss of viability within 60 seconds ( Fig. 2A Table 1 ). As negative controls, we used altered forms of SGP (SGP-L and SGP-E). In SGP-L, the central all alanine helix was replaced by an all leucine helix. In SGP-E, the dimension of one of the helices has been altered, and we had previously determined that the ability of such analogs to disrupt synthetic membranes is diminished
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. SGP-L and SGP-E were substantially less toxic to mammalian cultured cells ( Table 1 ). The LC 50 was increased by at least 10-fold in all cell types tested with SGP-L and SGP-E when these inactive versions of the protein were tested. These observations clearly show that the integrity of the SGP helices are required for SGP membrane disrupting activity. Taken together, these data demonstrate that SGP is a potent membrane-disrupting agent, but also that it is not selective and it will affect tumor derived cells as well as normal cells at similar concentrations (~3 mM).
SGP has anti-tumor activity in vivo.
Given the potent membrane-disrupting activity of SGP, we proceeded to evaluate SGP anti-tumor activity in nude mice bearing human tumor xenografts. We hypothesized that direct administration of SGP might reduce tumor volume and retard metastasis. In the first set of experiments, tumors were allowed to form after injection of a breast carcinoma cell line (MDA-MD-435), and then treated with local injections of SGP. We observed that tumor volume was significantly smaller in SGP treated mice than in the PBS treated control mice (Fig. 3A) . Starting tumor volumes ranged from about 100 mm 3 to large sizes of about 600 mm 3 . Tumor-bearing mice were given four weekly treatments of PBS, or 100 mM or 1 mM SGP (40 ml/treatment given in 5 ml increments).
After a 4-week period without treatment, the tumor volumes were measured at 8
weeks. The average tumor volume at the end of the experiment in the SGP treated groups was 5 times less than the average volume seen in the PBS-treated group ( Histopathological analysis of SGP-treated MDA-MD-435 human breast carcinoma xenografts showed widespread cell death (Fig. 4B) , as compared with PBS treated tumors (Fig. 4A) . Many condensed nuclei were apparent (Fig. 4B, short arrows) , and there was no effect on the extracellular matrix (Fig. 4B, long arrows) . Apoptosis was confirmed by a caspase-3 activation assay (data not shown). It is noteworthy that while 100 mM SGP induced almost immediate cell death in vitro that was apparently neither apoptotic nor necrotic, 100 mM SGP induced apoptosis in vivo. Work is underway to evaluate lower concentrations. SGP treated human KS1767 Kaposi's sarcoma-derived xenografts showed similar effects (Fig. 4C,D) . Histological analysis of the major organs of SGP treated mice showed no overt pathology, confirming that SGP treatments do not affect sites other than the injected tumor area (data not shown). Thus, SGP has anti "tumor" specific effects, without showing any "tumor cell" specific effects).
Mechanism of SGP action and selectivity towards cell membranes
To determine the mechanisms responsible for selective anti-tumor activity of SGP in vivo, we designed a matrigel assay (to mimic extracellular matrix). In the absence of matrigel, SGP led to severe disruption of cell membranes, resulting in almost 100% loss of viability over 10 min (Fig. 6B) . In contrast, in the presence of matrigel, KS1767 cells were unaffected by incubation with 1 mM SGP (Fig. 6D ). This loss of membrane disrupting ability in the presence of a thin matrigel layer could account for the lack of SGP toxicity seen in vivo. Ethanol, as shown in Fig. 6E , or cytotoxic drugs such as doxorubicin (Fig 7) damaged the cell layer under similar conditions, regardless of the presence of matrigel, which fails to provide protection from the other toxic agents because these other agents more readily diffuse through the matrix. When matrigel was replaced by polymeric fibronectin (sFN) 45 , another form of matrix, SGP was also ineffective and did not interfere with cell viability (Fig. 6 E) while ethanol induced massive cell death. Fibronectin alone did not prevent SGP activity and was used as a control.
The observations in this model are consistent with the lack of skin toxicity seen with SGP. We propose that the discrepancy between in vitro and in vivo SGP effects (antitumor cell activity versus selective anti-tumor activity) results from the potent membrane-disrupting activity of SGP, which is inactivated in the presence of ECM and connective tissue.
DISCUSSION
SGP represents an interesting class of anti-cancer proteins whose therapeutic effects can be optimized by amino acid substitution and by altering helical domain length and hydrophobicity 29, 35 . Although SGP is a non-specific membrane-disrupting agent, it is selective in the sense that the disruption is limited in vivo. Unlike detergents, which solubilize membranes, SGP physically disrupts membrane architecture, leading to cell lysis. This explains the lack of SGP toxicity when the protein is injected sub-cutaneously or intradermally. Recently published data also suggest that the lipid membrane- SGP activity appears to be restricted to the presence of lipid bilayers in vitro, while in vivo its activity appears to be limited to tumors in vivo due to the protective effect of extracellular matrix components. In vitro, SGP shows no selectivity towards normal or malignant cells, under the experimental conditions tested. We show here that SGP is potentially a valid anti-cancer agent; applications include Kaposi's sarcoma, malignant melanoma of the skin, or palliation for unresectable or metastatic tumors in anatomical sites difficult to treat with other modalities. Moreover, SGP variants in which residues critical for helical structure are altered are inactive, suggesting that the structure of the protein is intrinsically linked to its ability to damage cell membranes. Although the de novo design of proteins with biological function is in its early stages, novel therapeutic strategies may may emerge from the activity of designed proteins such as SGP. Table 1 . Comparative study of the properties of SGP and SGP mutants. --+  -----SGP  ---+  ----Matrigel + SGP  ----+  ---sFn  -----+  --sFN + SGP  ------+  -FN + SGP  ------ 
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